Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Blood (2025) 145 (3): 290–299.

https://doi.org/10.1182/blood.2024024681

Published: 2025

Includes: Supplemental data

Journal Articles

Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide

Noah Merin, Haein Kim, Yuliya Linhares, Akil Merchant, Justin M. Darrah, Joshua Sasine, Hannah Lee, Robert Allen Vescio, David Oveisi, Brittany McGalliard, Ali Rejali, Patricia VanStrien, Ellen B. Klapper, Behrooz Hakimian, John Chute, Ronald Paquette

Blood (2024) 144 (Supplement 1): 2104.

https://doi.org/10.1182/blood-2024-202176

Published: 2024

Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 460.

https://doi.org/10.1182/blood-2024-200992

Published: 2024

Journal Articles

Rituximab Ibrutinib Lenalidomide (R2I) Combination for Primary or Secondary Large B-Cell CNS Lymphoma: Last Resort or Bridge to Cellular Therapy?

Ariel Perez Perez, Tiba Al Sagheer, George Nahas, Muni Rubens, Kristie Lopes, Yazmin Odia, Manmeet Ahluwalia, Zhijian Chen, Yuliya Linhares

Blood (2023) 142 (Supplement 1): 6275.

https://doi.org/10.1182/blood-2023-186488

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Blood (2023) 142 (Supplement 1): 608.

https://doi.org/10.1182/blood-2023-173972

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Blood (2023) 142 (Supplement 1): 611.

https://doi.org/10.1182/blood-2023-172574

Published: 2023

Journal Articles

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Robert Allen Vescio, Yuliya Linhares, Ryan Ponec, Christopher Lopiccolo, Amanda Park, Rhona Castillo, Amrita Krishnan

Blood (2023) 142 (Supplement 1): 7057.

https://doi.org/10.1182/blood-2023-181957

Published: 2023

Journal Articles

Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in

Yuliya Linhares, Ariel Perez Perez, Tiba Al Sagheer, George Nahas, Alex Mejia-Garcia, Muni Rubens, Talia Zahra, Lyle Feinstein, Lisa Reale, Marco Andres Ruiz, Peter L. Citron, Yazmin Odia, Guenther Koehne

Blood (2022) 140 (Supplement 1): 12061–12063.

https://doi.org/10.1182/blood-2022-167064

Published: 2022

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Blood (2022) 140 (Supplement 1): 763–765.

https://doi.org/10.1182/blood-2022-156553

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Yuliya Linhares, Fei Fei Liu, Cesar Freytes, Mohamad Cherry, Ling Shi, Weiqin Liao, Julia Braverman, Ricardo Espinola, Min Vedal, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10930–10931.

https://doi.org/10.1182/blood-2022-159645

Published: 2022

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Blood (2022) 140 (Supplement 1): 9399–9401.

https://doi.org/10.1182/blood-2022-156576

Published: 2022

Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10416–10418.

https://doi.org/10.1182/blood-2022-159595

Published: 2022

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Blood (2021) 138 (Supplement 1): 2454.

https://doi.org/10.1182/blood-2021-147891

Published: 2021

Journal Articles

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Yuliya Linhares, MD, Mitul D Gandhi, Michael Chung, Jennifer Adeleye, David Ungar, Mehdi Hamadani, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136614

Published: 2020

Journal Articles

Pharmacologic Doses of Amiloride Preferentially Induce Apoptosis and Growth Inhibition of Flt3-ITD Mutation Positive Acute Myeloid Leukemia Cell Lines

Yuliya Linhares, M.D., Jade Dardine, M.D., Siavash Kurdistani, M.D.

Blood (2011) 118 (21): 5004.

https://doi.org/10.1182/blood.V118.21.5004.5004

Published: 2011

NARROW

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Rituximab Ibrutinib Lenalidomide (R2I) Combination for Primary or Secondary Large B-Cell CNS Lymphoma: Last Resort or Bridge to Cellular Therapy?

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Reverse Autologous Peripheral Blood Stem Cell Transplantation after Allogeneic Transplantation to Restore Immune Function and Pancytopenia

Trial in Progress: Zanubrutinib with Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial with a Safety Lead-in

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Pharmacologic Doses of Amiloride Preferentially Induce Apoptosis and Growth Inhibition of Flt3-ITD Mutation Positive Acute Myeloid Leukemia Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only